Patents by Inventor Marc Vimolratana

Marc Vimolratana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • Compounds that inhibit MCL-1 protein
    Patent number: 11306107
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20210230189
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 29, 2021
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
  • Compounds that inhibit MCL-1 protein
    Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200062780
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 27, 2020
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10494381
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: December 3, 2019
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Mike Elias Lizarzaburu, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190016736
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 17, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10100063
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 16, 2018
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20170088560
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: December 12, 2016
    Publication date: March 30, 2017
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Compounds that inhibit MCL-1 protein
    Patent number: 9562061
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: February 7, 2017
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Yunxiao Li, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Manuel Zancanella
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20160068545
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 10, 2016
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc VIMOLRATANA, Xianghong Wang, Ming Yu, Manuel ZANCANELLA, Liusheng Zhu, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Spirocyclic GPR40 modulators
    Patent number: 8748462
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: June 10, 2014
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
  • Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
    Patent number: 8450522
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: May 28, 2013
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
  • Substituted biphenyl GPR40 modulators
    Patent number: 8030354
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: October 4, 2011
    Assignee: Amgen Inc.
    Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jiwen Liu, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Yingcai Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
  • Heterocyclic GPR40 modulators
    Patent number: 8003648
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: August 23, 2011
    Assignee: Amgen Inc.
    Inventors: Hilary Beck, Paul Dransfield, Zice Fu, Jonathan B. Houze, XianYun Jiao, Todd J. Kohn, SuJen Lai, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang
  • SPIROCYCLIC GPR40 MODULATORS
    Publication number: 20110190330
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula IA, IB, I?A or I?B: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: October 13, 2009
    Publication date: August 4, 2011
    Applicant: AMGEN INC.
    Inventors: Sean P. Brown, Paul Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, XianYun Jiao, Sujen Lai, An-Rong Li, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang, Ming Yu, Liusheng Zhu
  • Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders
    Publication number: 20100298367
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: March 4, 2009
    Publication date: November 25, 2010
    Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
  • Heterocyclic GPR40 modulators
    Patent number: 7714008
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: May 11, 2010
    Assignee: Amgen Inc.
    Inventors: Hilary Beck, Paul Dransfield, Zice Fu, Jonathan B. Houze, XianYun Jiao, Todd J. Kohn, SuJen Lai, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang
  • HETEROCYCLIC GPR40 MODULATORS
    Publication number: 20100075974
    Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    Type: Application
    Filed: November 5, 2009
    Publication date: March 25, 2010
    Applicant: Amgen Inc.
    Inventors: Hilary Beck, Paul Dransfield, Zice Fu, Jonathan B. Houze, Xian Yun Jiao, Todd J. Kohn, SuJen Lai, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Michael J. Schmitt, Rajiv Sharma, Wang Shen, Marc Vimolratana, Yingcai Wang, Zhongyu Wang